PHOENIX ― Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.
Add A Comment